FDA-Approved Pharmacotherapies for MASH

Metabolic dysfunction-associated steatotic liver disease (MASLD), an increasingly prevalent condition among adults worldwide, is associated with liver-related complications, hepatocellular carcinoma, and certain extrahepatic cancers. Author Norbert Stefan, MD, from the University Hospital of Tübingen in Tübingen, Germany, discusses this and more with JAMA Deputy Editor Kristin Walter, MD, MS. Related Content:

• Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults

-----------------------------------

JAMA Editors' Summary